BCL-XL依赖是一种难以治疗的癌的亚型不可知可操作特征
Tupa Basuroy1, Treg Grubb1, Ananthan Sadagopan2
1Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH USA.
bioRxiv : the preprint server for biology
|December 19, 2025
概括
抗亡蛋白BCL-XL对清细胞细胞癌 (ccRCC) 和其他侵袭性癌至关重要. 增加AMPK异型2表达表明BCL-XL依赖,为患者分层提供了一个生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 清细胞细胞癌 (ccRCC) 取决于抗亡蛋白BCL-XL.
- 转移性和罕见的RCC亚型 (例如,FH缺乏,类) 中这种依赖的机制尚不清楚.
研究的目的:
- 研究各种RCC亚型中BCL-XL依赖的机制.
- 在难以治疗的RCC中识别BCL-XL依赖和患者分层的生物标志物.
主要方法:
- 在TCGA数据集上训练的机器学习模型用于计算预测.
- 基于细胞的验证和相关性研究.
- 功能性研究,以开发一个预测的多变量模型.
主要成果:
- 在所有RCC亚型中证实BCL-XL依赖.
- 细胞状态的变化,阿诺基斯,炎症和代谢干扰 (在FH缺乏的RCC中含有 fumarate) 会增加BCL-XL的依赖性.
- 增加AMPK异型2 (PRKAA2) 表达,被确定为BCL-XL依赖的脏特异性生物标志物.
结论:
- BCL-XL是挑战RCC的一个亚型不可知漏洞.
- AMPK异型2作为BCL-XL依赖的预测生物标志物.
- 在RCC中开发了患者分层和向治疗的模型.
相关概念视频
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


